An interventional study of Submucosal debridement and Submucosal debridement + titanium brushes in Peri-implantitis, Titanium Brush and Non-surgical Submucosal Debridement, sponsored by Universitat Internacional de Catalunya. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Universitat Internacional de Catalunya · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya — 6 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Universitat Internacional de Catalunya.
Among the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, this one is one of 2 that started in 2024, is one of 7 with no phase, and was the 14th registered.
324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.
Browse Peri-Implantitis studies →6 of the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya are open now, in 1 country. Recruiting first, the newest first:
Universitat Internacional de Catalunya · Sites in Spain
Ages 18+ · Healthy volunteers
Universitat Internacional de Catalunya · Sites in Spain
Ages 18–80
Universitat Internacional de Catalunya · Sites in Spain
Ages 21–80 · Healthy volunteers
Universitat Internacional de Catalunya · Sites in Spain
Ages 18+
Universitat Internacional de Catalunya
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 36 is close to the median of 40 across 196 interventional studies indexed under Peri-Implantitis.
Median enrollment 36 across the 9 interventional studies, 143 across the 6 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Universitat Internacional de Catalunya is the lead sponsor of 151 studies on the registry; 46 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Peri-implantitis is a plaque-associated condition occurring around dental implants, characterized by inflammation in the peri-implant mucosa and loss of supporting bone. To stop this progression, mechanical debridement of biofilm and calculus is commonly used to treat peri-implant lesions as well as the use of adjunctive measures such as titanium brushes. As observed, they improved plaque removal when compared with steel curettes alone. Therefore, it is of interest to evaluate the impact of this procedure in terms of clinical, radiographic and microbiological outcomes to assess their efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive submucosal debridement alone
Device: Submucosal debridement · Device: Submucosal debridement + titanium brushes
Participants will receive submucosal debridement and titanium brushes
Device: Submucosal debridement · Device: Submucosal debridement + titanium brushes
Participants will undergo non-surgical submucosal debridement alone (SD)
Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)
Pocket depth changes
The primary outcome variable will be pocket depth changes at 1 year of follow-up.
Time frame: 12 Months
Full mouth plaque index (FMPI)
Assessed dichotomously as presence or absence of plaque will be scored if present along the gingival margin and if it can be removed with the side of the probe. The percentage of surfaces with plaque out of the total number of examined tooth surfaces will be calculated.
Time frame: 12 Months
Full mouth bleeding index (FMBI)
Assessed dichotomously as presence or absence of bleeding after 30 seconds of gently probing. The proportion of bleeding surfaces out of the total number of examined surfaces will be calculated.
Time frame: 12 Months
Modified plaque index (mPI)
* Score 0: no detection of plaque. * Score 1: plaque only recognized by running a probe across the smooth marginal surface of the implant. * Score 2: plaque can be seen by the naked eye. * Score 3: abundance of soft matter.
Time frame: 12 Months
Modified bleeding index (mBI)
* Score 0: no bleeding. * Score 1: isolated bleeding spots visible. * Score 2: blood forms a confluent red line on margin. * Score 3: heavy or profuse bleeding.
Time frame: 12 Months
Suppuration on probing (SoP)
Presence or absence of suppuration after gentle probing.
Time frame: 12 Months
Mucosal recession (MR)
Distance (mm) from the mucosal margin and the interface between implant and abutment.
Time frame: 12 Months
Keratinized mucosa (KM)
Distance (mm) from the mucosal margin to the mucogingival junction at the midbuccal aspect of the implant.
Time frame: 12 Months
Radiographic parameters
Marginal bone level (MBL): distance (mm) between the implant shoulder and the base of the defect at the mesial and distal aspect.
Time frame: 12 Months
Radiographic parameters
Intra-bony defect (ID): distance (mm) between the bottom of the defect and the line connecting the distal and mesial inter-proximal bone crest.
Time frame: 12 Months
Radiographic parameters
Intra-bony defect width (WD): distance (mm) between the distal and mesial inter- proximal bone crest and the implant surface.
Time frame: 12 Months
Radiographic parameters
Angulation of the intra-bony defect (AD): angle resulted from a vertical line along the outer implant surface and a line extending along the peri-implant bone defect.
Time frame: 12 Months
Microbiological analysis
Total bacterial load (CFU/ml) Microbiome alpha-diversity
Time frame: 12 Months
Microbiological analysis
Total bacterial load (CFU/ml) Microbiome beta-diversity
Time frame: 12 Months
Microbiological analysis
Total bacterial load (CFU/ml) Relative and differential bacterial genera abundance at different timepoints
Time frame: 12 Months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jul 2025, 13 months after the start.
Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 13 months is below that.
Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitat Internacional de Catalunya →